FDA Inspection 1002326 — Ursula Matulonis
The FDA completed an inspection of Ursula Matulonis on Feb 7, 2017 in Boston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 7, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Boston, MA (United States)
Additional Details
Clinical Investigator (CI)